View Post

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer

In Clinical Trials by Barbara Jacoby

From: thelancet.com A randomised, non-inferiority, open-label, phase 3 trial Background To our knowledge, no randomised study has compared postmastectomy hypofractionated radiotherapy with conventional fractionated radiotherapy in patients with breast cancer. This study aimed to determine whether a 3-week schedule of postmastectomy hypofractionated radiotherapy is as efficacious and safe as a 5-week schedule of conventional fractionated radiotherapy. Methods This randomised, non-inferiority, …

View Post

High-dose radiation therapy improves long-term survival in patients with stage-IV cancers, trial finds

In Clinical Trials by Barbara Jacoby

Source: American Society for Radiation Oncology From: sciencedaily.com The first report from a phase II, multi-center clinical trial indicates that a newer, more aggressive form of radiation therapy — stereotactic radiation — can extend long-term survival for some patients with stage-IV cancers while maintaining their quality of life. The study is published in the January issue of International Journal of …

View Post

The Pain Clinic – Solving the five most common problems in clinical trials

In Clinical Trials by Barbara Jacoby

At Partnerships in Clinical Trials in Barcelona (Nov 2018), Kate O’Brien, formally a senior research nurse and now a site consultant, led a problem solving forum for all aspects of running clinical trials. Here she examines the most common problems and the potential solutions to them. The concept behind this initiative was to identify some of the issues that face different areas of …

View Post

Translating Patient Feedback Into Better Cancer Treatments

In Clinical Trials by Barbara Jacoby

From: Cedars-Sinai A major new study now underway aims to better incorporate patient feedback into clinical trials that help determine which new cancer treatments will be approved for use. The project, supported by a five-year, $3.4 million grant from the National Cancer Institute, involves statisticians, clinicians and patient advocates. The team is analyzing data from previous and ongoing clinical trials …

View Post

John Theurer Cancer Center Leading Enrollment for Global Phase 2 WIZARD Study Evaluating DSP-7888 in Patients with Recurrent Glioblastoma

In Clinical Trials by Barbara Jacoby

Source: John Theurer Cancer Center From: prnewswire.com John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center announced today that it is leading enrollment worldwide for WIZARD 201G, a global Phase 2 study in glioblastoma (GBM). The trial, sponsored by Boston Biomedical, is evaluating DSP-7888, an investigational cancer vaccine, in combination with bevacizumab for recurrent disease. Glioblastoma is the …

View Post

Servier, in Collaboration with Allogene Therapeutics, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T) Therapy

In Clinical Trials by Barbara Jacoby

Source: Allogene Therapeutics Allogene to Initiate the ALPHA Study for ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma ALLO-647, Allogene’s Proprietary anti-CD52 Antibody, Will be Administered as Part of the Lymphodepletion Regimen Paris (France) and South San Francisco, Calif. – January 28, 2019 – Servier, an independent international pharmaceutical company and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical- stage biotechnology company pioneering the …

View Post

New breast imagine modality may reduce unnecessary biopsies by up to 45 percent

In Clinical Trials by Barbara Jacoby

By: Lisa Chamoff From: dotmed.com Researchers at Washington University in St. Louis predict a new breast imaging modality that combines ultrasound and near-infrared imaging, or diffuse light tomography, can reduce unnecessary biopsies by up to 45 percent. The team — Quing Zhu, professor of biomedical engineering at the Washington University in St. Louis School of Engineering & Applied Science and …

View Post

OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer

In Clinical Trials by Barbara Jacoby

Source: OncoQuest, Inc. From: prnewswire.com OncoQuest Inc., a privately held, cancer immunotherapy company, has retained the services of IQVIA, a company formed through the merger of IMS Health and Quintiles, to manage OncoQuest’s planned Phase 3 clinical study in frontline ovarian cancer with the company’s lead product candidate, oregovomab, an anti-CA-125 antibody. OncoQuest will collaborate with IQVIA, a leading global …

View Post

Inovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor

In Clinical Trials by Barbara Jacoby

From: prnewswire.com Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that a second patient with HPV-related head and neck cancer treated with INO-3112 (now called MEDI0457) in a Phase 1 trial achieved a sustained complete response (full remission) after subsequent treatment with a PD-1 checkpoint inhibitor. This marks the second patient with metastatic cancer observed in full remission (complete response) after treatment …